• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.

作者信息

Wörns Marcus-Alexander, Galle Peter R

机构信息

Department of Internal Medicine I and the Cirrhosis Centre Mainz (CCM), University Medical Centre of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany.

出版信息

Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):74-76. doi: 10.1038/nrgastro.2017.174. Epub 2018 Jan 4.

DOI:10.1038/nrgastro.2017.174
PMID:29300046
Abstract
摘要

相似文献

1
Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.2017年肝细胞癌：前进两大步，后退一小步。
Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):74-76. doi: 10.1038/nrgastro.2017.174. Epub 2018 Jan 4.
2
Which treatment modality should we choose for advanced hepatocellular carcinoma?对于晚期肝细胞癌，我们应该选择哪种治疗方式？
Korean J Hepatol. 2010 Dec;16(4):353-4. doi: 10.3350/kjhep.2010.16.4.353.
3
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.肝动脉灌注化疗与索拉非尼治疗经动脉化疗栓塞难治性肝细胞癌患者的疗效比较
Anticancer Res. 2016 Jul;36(7):3523-9.
4
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.比较有大血管侵犯和经导管动脉化疗栓塞耐药状态的晚期肝细胞癌患者行肝动脉灌注化疗和索拉非尼治疗的临床结局。
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
5
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Asia Pac J Clin Oncol. 2012 Jun;8(2):111-4. doi: 10.1111/j.1743-7563.2012.01551.x.
6
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗肝细胞癌。
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
7
Closing remarks.结束语。
Clin Drug Investig. 2012 Aug 8;32 Suppl 2:52. doi: 10.2165/1163025-S0-000000000-00000.
8
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的安全性
Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.
9
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.索拉非尼联合经动脉化疗栓塞术及支气管动脉化疗灌注治疗肺转移肝细胞癌
Asia Pac J Clin Oncol. 2012 Jun;8(2):156-63. doi: 10.1111/j.1743-7563.2012.01542.x.
10
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].索拉非尼联合经动脉化疗栓塞术/肝动脉灌注化疗成功治疗转移性肝细胞癌
Gan To Kagaku Ryoho. 2014 Nov;41(12):2110-2.

引用本文的文献

1
Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.克霉唑通过调节 ERK-p65 信号通路抑制 HCC 迁移和侵袭。
Drug Des Devel Ther. 2022 Mar 29;16:863-871. doi: 10.2147/DDDT.S354205. eCollection 2022.
2
circSLC30A7 Inhibits Hepatocellular Carcinoma Cell Proliferation via the miR-767-5p/FBXW7/NOTCH1 Axis.
J Oncol. 2021 Oct 12;2021:8800657. doi: 10.1155/2021/8800657. eCollection 2021.
3
Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report.多学科治疗伴有严重门脉-动脉分流的晚期肝细胞癌 1 例报告。

本文引用的文献

1
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.索拉非尼联合经动脉化疗栓塞治疗不可切除肝细胞癌（TACE 2）：一项随机安慰剂对照、双盲、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.
2
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
3
J Int Med Res. 2021 Jul;49(7):3000605211024840. doi: 10.1177/03000605211024840.
4
Anti-Cancer Effect of Moroccan Cobra Venom and Its Fractions against Hepatocellular Carcinoma in 3D Cell Culture.摩洛哥眼镜蛇毒液及其组分对 3D 细胞培养肝癌的抗癌作用。
Toxins (Basel). 2021 Jun 4;13(6):402. doi: 10.3390/toxins13060402.
5
TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.跨膜蛋白106C（TMEM106C）促进肝细胞癌的恶性特征和不良预后。
Aging (Albany NY). 2021 Feb 11;13(4):5585-5606. doi: 10.18632/aging.202487.
6
Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR‑153‑3p.Hsa_circ_0008537 通过上调 miR-153-3p 表达促进肝癌发生发展。
Oncol Rep. 2021 Mar;45(3):1072-1082. doi: 10.3892/or.2021.7941. Epub 2021 Jan 19.
7
CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation.CD63 通过抑制炎性细胞因子诱导的 STAT3 激活负调控肝细胞癌的发展。
J Cell Mol Med. 2021 Jan;25(2):1024-1034. doi: 10.1111/jcmm.16167. Epub 2020 Dec 4.
8
High pre-treatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma.治疗前较高的静态和动态甲胎蛋白值预示着肝细胞癌患者总生存期缩短。
United European Gastroenterol J. 2020 Nov 23;9(3):2050640620972611. doi: 10.1177/2050640620972611.
9
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.当有多种疗法可供选择时，该如何抉择？晚期肝细胞癌的当前全身治疗方法。
Health Sci Rep. 2020 Jan 29;3(1):e147. doi: 10.1002/hsr2.147. eCollection 2020 Mar.
10
Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11.环状 RNA 0001955 通过海绵吸附 miR-516a-5p 释放 TRAF6 和 MAPK11 促进肝细胞癌 (HCC) 肿瘤发生。
Cell Death Dis. 2019 Dec 10;10(12):945. doi: 10.1038/s41419-019-2176-y.
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.TACE 治疗后中晚期肿瘤：从手术到系统治疗。
J Hepatol. 2017 Jul;67(1):173-183. doi: 10.1016/j.jhep.2017.03.007. Epub 2017 Mar 18.
4
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
5
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
6
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.基于证据的肝细胞癌患者诊断、分期和治疗。
Gastroenterology. 2016 Apr;150(4):835-53. doi: 10.1053/j.gastro.2015.12.041. Epub 2016 Jan 12.
7
HCC therapies--lessons learned.肝癌治疗——经验教训。
Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):447-52. doi: 10.1038/nrgastro.2014.10. Epub 2014 Feb 4.
8
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.